Skip to main content
  • Phase 2 Results Demonstrate Safety and Efficacy for FXIa Inhibitor Asundexian

    Treatment with the Factor XI activity inhibitor asundexian results in significantly lower rates of bleeding compared with apixaban and is well-tolerated, according to new data from the Phase 2 dose-finding PACIFIC-AF trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details